1.. BACKGROUND
==============

Blunt thoracic aortic injuries (BTAIs) are the second leading cause of death from blunt trauma after head injury and although they account for less than 1% of trauma admissions, they have significantly high morbidity and mortality rates. Pre-hospital mortality is as high as 85% and even of the remaining 15%, a third will die before interventional treatment is provided \[[@R1],[@R2]\].

Arthurs and colleagues (2009), analysing data from the National Trauma Data Bank, found that, in a 5 year period, 3114 patients suffered a BTAI, representing 0.3% of all trauma admissions (n=1.1 million) in the USA \[[@R3]\].

Clinical presentation is non-specific and may range from absence of symptoms to pain and these of severe hypovolaemic shock. Proper diagnostic approach is of paramount importance for these patients because of the high mortality of BTAIs \[[@R4]\].

With regards to diagnosis, there has been a shift from classic angiography, which used to be the diagnostic modality of choice in the past, to emergency CT scan. This shift represents one of the major advancements in the management of BTAIs and CT angiography is now the preferred screening tool and gold standard for diagnostic confirmation and delineation as well as evaluation and grading of these injuries \[[@R4]-[@R6]\].

Treatment of patients with BTAIs may be interventional (immediate or delayed, surgical or endovascular repair) or conservative (medical therapy), and this is largely dependent on clinical judgement on an individual basis. With regards to the best timing of intervention, the decision should be made based on the presence and severity of symptoms and related complications, comorbidities and the presence or absence of other injuries \[[@R4]\].

Interventional treatment for BTAIs can be either surgical \[open repair (OR)\] or endovascular \[thoracic endovascular aortic repair (TEVAR)\]; TEVAR started to gain popularity after the first reported case series of the use of thoracic stent grafts for thoracic aortic pathology by Dake *et al.* in 1994 \[[@R7]\].

Beyond the commonly-encountered perioperative complications, the repair of BTAIs may lead to more specific complications, such as paraplegia and stent endoleaks, which represent the most common complications of OR and TEVAR respectively.

Notably, paraplegia is substantially more common after OR than after TEVAR, and this is most likely due to clamping and prolonged hypotension and extension of aortic trauma in the former as well as the short segment of aorta stented in the latter and its relation to the blood supply of the spinal cord \[[@R5]\]. However, despite the favorable results of TEVAR over OR in terms of mortality and paraplegia, the durability and long-term complications of endovascularly repairing BTAIs still remain uncertain as only a limited number of studies that describe long-term results have been published \[[@R8],[@R9]\].

2.. PROGRESS IN THE MANAGEMENT OF BTAIs
=======================================

A report of paramount significance illustrating the important changes in clinical practice was published by Demetriades *et al.* (2008). The authors compare and analyse the findings of two studies conducted by the American Association for the Surgery of Trauma in 1997 and 2007 that describe the management of BTAIs \[[@R10]\].

In the first study, classic angiography was performed in 87% and CT scan in 34.8% of patients, while in the second one, only 8.3% patients underwent classic angiography due to the marked increase in the use of CT scan (93.3%) \[[@R10]\].

The authors note three major shifts in the definitive treatment of BTAIs: 1) the time from admission to definitive treatment was significantly longer in 2007 compared with 1997 (mean=54.6 hours versus mean=16.5 hours respectively); 2) the treatment of choice shifted from open surgery in 1997 (100% of cases) to TEVAR in 2007 (64.8% of cases); 3) in 2007, bypass techniques were noted to be used more liberally during ORs than in 1997 \[[@R10]\].

These changes in the diagnostic work-up and interventional treatment of BTAIs seem to be beneficial, as mortality and procedure-related paraplegia dropped significantly between 1997 and 2007, from 22.0% to 13.0% and from 8.7% to 1.6% respectively. Furthermore, paraplegia rates in ORs exclusively fell significantly from 8.7% to 2.9% between the two studies, most likely due to the increasing use of cardiopulmonary bypass support, spinal cord protection, and sequential cross-clamping. The only negative outcome described was the increase in early graft-related complications from 0.5% in 1997 to 13.5% in 2007 (endoleaks, aortic puncture injuries, impairment of subclavian artery flow, strokes and paraplegia) \[[@R10]\].

3.. RELEVANT LITERATURE
=======================

Recently published observational studies and meta-analyses favour the use of the endovascular method as definitive treatment over OR in patients with BTAIs and support delaying repair of the injuries where possible \[[@R11]-[@R25]\].

Six (6) meta-analyses were identified in the literature and all were in favour of TEVAR in terms of both mortality (odds ratio 0.31-0.61) and paraplegia (odds ratio 0.23-0.34) \[[@R11]-[@R16]\]. Further to the above parameters, Tang *et al.* (2008) reported lower stroke rates of TEVAR (0.85%) compared with OR (5.3%) and equal technical success rates between the two treatment methods, while Hoffer *et al.* (2008) reported a 4.2% incidence of endoleaks in BTAIs treated with TEVAR \[[@R9]\]. Apart from the overall lower procedure-related mortality of TEVAR compared with OR (odds ratio 0.31) described by Xenos *et al.* (2008), 30-day mortality was also significantly lower in the TEVAR group (odds ratio 0.44) in the same study \[[@R12]\].

Finally, Murad *et al.* (2011) included a "no treatment" group in their meta-analysis, which had higher mortality rates (19%) than TEVAR (9%) but lower than OR (46%). The risk of spinal cord ischaemia and end-stage renal failure was higher in the OR group (9% and 8% respectively) compared to TEVAR (3% and 5% respectively) and no treatment (3% and 3% respectively) groups, and there was no difference in stroke rates among the three groups \[[@R13]\].

Two large prospective studies are also in support of the use of TEVAR compared with OR as the former treatment method yielded lower mortality rates \[[@R17],[@R18]\]. In the study by Demetriades *et al.* (2008), mortality in the TEVAR group was lower in patients with and without extra-thoracic injuries (odds ratio 8.42) and additionally, fewer transfusion units (mean difference 4.98) were required for TEVAR patients. Paraplegia rates were similar in the two groups \[[@R17]\]. Azizzadeh and colleagues (2011) described an estimated odds ratio of 0.33 for complications (including in-hospital mortality) with TEVAR compared with OR, similar costs, and similar length of hospital stay \[[@R18]\].

In another prospective study by Demetriades *et al.* (2009), where early and late repair were compared, stable BTAI patients who underwent late repair had lower mortality rates (odds ratio 7.78) and similar complication rates. Finally, the late repair group had a longer mean ICU and hospital lengths of stay \[[@R19]\].

Interestingly, of the 6 large retrospective studies analysed, only 3 \[Arthurs *et al.* (2009), Branco *et al.* (2014), Estrera *et al.* (2010)\] found lower death rates in BTAIs repaired with TEVAR compared with those treated with OR \[[@R20]-[@R25]\].

Arthurs *et al.* (2009) performed a 5 year analysis of the National Trauma Data Bank (USA) and reported equal survival rates between the two groups, however TEVAR was superior to OR in terms of survival when repair was delayed (0% *vs.* 12%). Similar paraplegia rates in TEVAR and OR groups were described in the same study, however the latter group suffered higher rates of acute respiratory distress syndrome (2% *vs.* 7%), pneumonia (12% *vs.* 18%), myocardial infarction (4% *vs.* 25%) and acute kidney injury (6% *vs.* 10%) \[[@R3]\]. Five years later, Branco *et al.*(2014), after a 9 year analysis of the same data bank, described favorable outcomes of the endovascular approach compared with OR in terms of in-hospital mortality (12.9% *vs.* 22.4%) and sepsis (5.4% *vs.* 7.5%) \[[@R20]\].

In the study by Estrera *et al.* (2010) that reported lower mortality rates of TEVAR (0%) compared with OR (14% with and 31% without distal aortic perfusion), delayed repair (mortality 2%) was superior to early repair (mortality 28%) and, specifically in the OR group, mortality and paraplegia rates were higher in those who underwent distal aortic perfusion (14% and 0% respectively) compared with those who did not (31% and 10% respectively). Paraplegia rates were similar between TEVAR and OR groups \[[@R21]\].

In a study by Patel *et al.* (2011) where freedom from re-intervention was compared, zero patients required another procedure in the OR group (0%) compared with 1 patient treated with TEVAR (6%) \[[@R20]\]. According to Estrera and colleagues (2013), TEVAR was statistically superior to OR with cross-clamping but not to OR with distal aortic perfusion, in terms of survival (4%, 31% and 14% respectively). In the same study survival at 1 and 5 years post-intervention was 76% and 75% respectively for OR, and 92% and 87% for TEVAR \[[@R23]\].

Finally, Di Eusanio *et al.* (2013) found that delayed repair was used as first-line treatment for BTAIs and was associated with a very low mortality (3.9%). Comparing TEVAR and OR groups, mortality and paraplegia rates were not different \[[@R24]\].

Azizzadeh *et al.* (2014) supported that mid-term outcomes (median follow-up 2.3 years, range 0-7 years) of TEVAR make it a safe and durable method for BTAIs, having reported small percentages of in-hospital mortality (5.0%), stroke (2.4%), paraplegia (0%), and device-related complications (2.4%) \[[@R25]\].

A recent study by Canaud *et al.* (2015) described data of follow-up of minimum 10 years post-TEVAR (mean 11.6 years) with very encouraging results. The authors showed that the favorable outcomes of TEVAR over OR in terms of mortality and complications last over time, as none of the 53 patients with acute traumatic transection of the thoracic aorta treated endovasculalry died or had any device-related complications \[[@R9]\].

Karmy-Jones *et al.* (2011), who included 62 retrospective reviews and 6 meta-analyses in their well-presented systematic review (2005-2010), concluded that TEVAR had a lower mortality and lower incidences of paraplegia compared with OR although the former was performed in older patients, however, a statistically significant survival benefit was reported only in 4 papers \[[@R26]\].

The authors, considering the findings of Demetriades *et al.* (2009) described above, suggest delaying repair for patients with either significant injury or reversible physiologic derangement \[[@R19],[@R26]\].

With respect to paraplegia after TEVAR, Scali *et al.* (2014) identified 5 predictors that influence the risk of spinal cord ischaemia. The authors described age, aortic coverage length, Chronic Obstructive Pulmonary Disease, chronic kidney disease and hypertension determining the risk of post-TEVAR paraplegia and produced a simple clinical tool to assist decision-making about the choice of definitive treatment and guide the implementation of protective strategies \[[@R27]\].

4.. GUIDELINES
==============

For the treatment of BTAIs, recent clinical practice guidelines by the Society for Vascular Surgery advocate that TEVAR should be used preferentially over OR or non-operative management, and repair should be performed urgently (\<24 hours). Expectant management is recommended for minimal aortic injuries with serial imaging for type I injuries, and TEVAR is advised for young patients, regardless of age, if anatomical criteria are permissive \[[@R28]\].

These latter recommendations are in accordance with the more recently-published guidelines of the Task Force for the Diagnosis and Treatment of Aortic Diseases of the ESC, that advise the use of TEVAR in suitable anatomies (Level of Evidence: C). With respect to diagnosis, upon suspicion of a traumatic aortic injury, including BTAIs, CT should be used and, if not available, TOE should be considered, according to the guidelines (Level of Evidence: C) \[[@R29]\].

Additionally, with regards to long-term surveillance and more specifically the detection of endoleaks, pseudoaneurysms and stent graft material-related complications, they recommend the combination of a chest X-ray with either MRI or CT scan. Although CT is currently the preferred modality, they advise considering the dangers of radiation, especially in younger patients, and suggest the use of MRI except in cases of magnetic resonance-incompatible grafts \[[@R29]\].

With respect to the use of TEVAR exclusively, the most recent guidelines suggest that TEVAR is indicated for patients with complete transection of the aortic wall and haemorrhage into the mediastinum and those with pseudocoarctation syndrome; according to the same guidelines, limited disruption of the aorta with intact intima and media should be managed expectantly with conservative management \[[@R30]\].

CONCLUSION
==========

During the last years, there have been major, innovative advancements in the management of BTAIs. Published reports indicate that CT scans are now used as the diagnostic modality of choice.

Additionally, endovascular repair should be used in preference to open surgical repair or medical treatment, taking into consideration the lower mortality and paraplegia rates on one hand, and the anatomy, pathology and comorbidities of the other. The final decision should be made on an individual basis by a multidisciplinary approach regarding the type and timing of intervention.

Continued surveillance is essential for the early detection of potential complications and adverse effects and improvement of the design of the endografts is required for the avoidance of graft-related complications and longer survival of the grafts in BTAIs repaired with TEVAR. Finally, the absence of extensive long-term follow-up data for TEVAR should carefully be considered when the endovascular approach is chosen for definitive treatment of BTAIs.
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